Danaher Co. (NYSE:DHR) Stake Reduced by Duncker Streett & Co. Inc.

Duncker Streett & Co. Inc. lowered its holdings in Danaher Co. (NYSE:DHR) by 3.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,501 shares of the conglomerate’s stock after selling 1,719 shares during the quarter. Danaher accounts for 2.2% of Duncker Streett & Co. Inc.’s holdings, making the stock its 9th largest holding. Duncker Streett & Co. Inc.’s holdings in Danaher were worth $12,052,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. FMR LLC raised its position in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. Van ECK Associates Corp raised its position in Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after purchasing an additional 916,513 shares during the period. Proficio Capital Partners LLC raised its position in Danaher by 29,287.7% in the fourth quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after purchasing an additional 586,925 shares during the period. Massachusetts Financial Services Co. MA raised its position in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. Finally, Fisher Funds Management LTD acquired a new stake in shares of Danaher in the fourth quarter valued at $120,718,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company’s stock.

Danaher Trading Up 1.0 %

NYSE:DHR opened at $207.73 on Friday. The stock has a 50-day simple moving average of $224.58 and a 200-day simple moving average of $244.92. The stock has a market cap of $148.47 billion, a P/E ratio of 39.34, a P/E/G ratio of 2.66 and a beta of 0.83. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the company posted $2.09 earnings per share. As a group, analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio is currently 24.24%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. JPMorgan Chase & Co. dropped their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Jefferies Financial Group dropped their price objective on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. The Goldman Sachs Group set a $250.00 price objective on Danaher in a research note on Wednesday, January 15th. Finally, Citigroup dropped their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.